

# WOAH Reference Laboratory Reports Activities 2024

This report has been submitted: 21 janvier 2025 01:07

# LABORATORY INFORMATION

*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Bovine spongiform encephalopathy	
*Address of laboratory:		
*Tel:	+81-29 838 7835	
*E-mail address:	gan@affrc.go.jp	
Website:	https://www.naro.go.jp/english/laboratory/niah/index.html	
*Name (including Title) of Head of Laboratory (Responsible Official):	Ken KATSUDA (Director-General) National Institute of Animal Health, NARO	
*Name (including Title and Position) of WOAH Reference Expert:	Yoshifumi IWAMARU (Head of Virus Group)	
*Which of the following defines your laboratory? Check all that apply:	Research agency	

### **TOR1: DIAGNOSTIC METHODS**

Yes

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally

WOAH Reference Laboratory Reports Activities 2024



#### Yoshifumi Iwamaru - - JAPAN

PRNP genotyping	No	751	0
Direct diagnostic tests		Nationally	Internationally
WB tests for TSE surveillance	Yes	751	0

### **TOR2: REFERENCE MATERIAL**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAH Members?

No

### **TOR3: NEW PROCEDURES**

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease? No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

No

### **TOR4: DIAGNOSTIC TESTING FACILITIES**

10. Did your laboratory carry out diagnostic testing for other WOAH Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?

Yes

Name of the WOAH Member Country receiving a technical consultancy	Purpose	How the advice was provided
INDONESIA	Request for the SOP of the immunohistochemistry test for BSE.	Provides the SOP via email

### **TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES**

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

No

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOAH?



#### No

# **TOR6: EPIZOOLOGICAL DATA**

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

b) International conferences:

#### 1

An update on animal transmissible spongiform encephalopathies (TSE), Yoshifumi Iwamaru, Asian Pacific Prion Symposium 2024

c) National conferences:

d) Other (Provide website address or link to appropriate information):

### **TOR7: SCIENTIFIC AND TECHNICAL TRAINING**

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

Yes

a) Technical visit : 0

b) Seminars : 0

c) Hands-on training courses: 1

d) Internships (>1 month) 6

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
С	BRAZIL	2

WOAH Reference Laboratory Reports Activities 2024



#### Yoshifumi Iwamaru - - JAPAN

D	ERITREA	1
D	PAPUA NEW GUINEA	1
D	PHILIPPINES	1
D	UGANDA	1
D	UZBEKISTAN	1
D	PARAGUAY	1

### **TOR8: QUALITY ASSURANCE**

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO/IEC 17025:2017	PDF	img20231207_09221963.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Western Blot	Japan Accreditation Board

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Biosafety Committee for managing pathogens is in place. We have biosafety procedures and comply with national regulations. We have annual biosafety educational program.

### **TOR9: SCIENTIFIC MEETINGS**

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?

No

### **TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES**

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease? Yes

24. Do you network (collaborate or share information) with other WOAH Reference Laboratories designated for the same pathogen? No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen during the past 2 years?

Yes



#### Yoshifumi Iwamaru - - JAPAN

Purpose of the proficiency test:	Role of your Reference Laboratory (organiser/ participant)	No. participating Laboratories	Participating WOAH Ref. Labs/ organising WOAH Ref Lab
BSE Rapid Tissue Test (PT0124)	participant	18	-

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Vee

Title of the project or contract	Scope	Name(s) of relevant WOAH Reference Laboratories
TSE diagnosis	To improve PMCA method	OIE Ref Lab for CWD, Korea(REP. OF)

### **TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING**

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen during the past 2 years?

Purpose for inter- laboratory test comparisons1	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAH Member Countries
A proficiency test for TSE diagnosis	ORGANIZER	1	WB test	JAPAN,

# **TOR12: EXPERT CONSULTANTS**

28. Did your laboratory place expert consultants at the disposal of WOAH?

Yes

Kind of consultancy	Location	Subject (facultative)	
Kind of consultancy	Location		
ad hoc Group meetings	WOAH Headquarters in Paris	To revise Terrestrial Code Chapter 14.8. Scrapie.	
ad hoc Group meetings	WOAH Headquarters in Paris	To assess BSE risk status of members	

29. Additional comments regarding your report:

Yes

Since the countermeasures against BSE have worked so well, the BSE prevalence drastically decreased and stays low worldwide. Nowadays only several BSE cases (two cases in 2024) were reported. Particularly, in the Asia and Oceania region, no BSE case has been reported except for Japan. Under these circumstances, simply we did not

have chance to carry out the international diagnostic activity nor supply of reference material. We predict that this situation will not change suddenly.